Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares UltraPro Short QQQ ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while ProShares UltraPro Short QQQ ETF trades at $37.47. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SQQQ | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $25.45 | $92.95 |
52-Week Low | $12.30 | $36.31 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.32, down 1.11% amid a bearish technical signal with moving averages indicating selling pressure. The ETF is designed to deliver -3x the daily performance of the Nasdaq-100, making it highly sensitive to tech sector volatility. Recent news highlights its role as a tactical hedge tool but warns of significant long-term erosion due to daily reset mechanics.
The outlook for SQQQ remains high-risk, suitable only for short-term hedging against Nasdaq declines. Key risks include volatility decay from daily leverage and dependency on precise market timing. Investor sentiment is cautious, with analysts emphasizing its unsuitability as a long-term holding despite potential tactical opportunities during tech selloffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
